Overview

OTO-201 for the Treatment of Otitis Externa

Status:
Completed

Trial end date:
2015-11-01

Target enrollment:

Participant gender:

Summary

This is a 1-month, multicenter, open-label study in subjects with unilateral otitis externa. Eligible subjects will receive a single dose of 6 mg OTO-201 to the affected ear. The study is designed to characterize safety, procedural factors and clinical effect of OTO-201 administered in subjects with otitis externa.

Phase:

Phase 2

Details

Lead Sponsor:

Otonomy, Inc.

Treatments:

Ciprofloxacin